Cargando…

Chinese herbal medicine TangBi Formula treatment of patients with type 2 diabetic distal symmetric polyneuropathy disease: study protocol for a randomized controlled trial

BACKGROUND: Diabetic distal symmetric polyneuropathy (DSPN) is one of the most common microvascular complications of diabetes mellitus, and it has become a major public health problem worldwide because of its high and increasing prevalence, morbidity, and disability rate. The current medications for...

Descripción completa

Detalles Bibliográficos
Autores principales: Jin, De, Huang, Wen-jing, Meng, Xiang, Yang, Fan, Zheng, Yu-jiao, Bao, Qi, Zhang, Mei-zhen, Yang, Ya-nan, Ni, Qing, Lian, Feng-mei, Tong, Xiao-lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5747122/
https://www.ncbi.nlm.nih.gov/pubmed/29284520
http://dx.doi.org/10.1186/s13063-017-2345-1
_version_ 1783289224768782336
author Jin, De
Huang, Wen-jing
Meng, Xiang
Yang, Fan
Zheng, Yu-jiao
Bao, Qi
Zhang, Mei-zhen
Yang, Ya-nan
Ni, Qing
Lian, Feng-mei
Tong, Xiao-lin
author_facet Jin, De
Huang, Wen-jing
Meng, Xiang
Yang, Fan
Zheng, Yu-jiao
Bao, Qi
Zhang, Mei-zhen
Yang, Ya-nan
Ni, Qing
Lian, Feng-mei
Tong, Xiao-lin
author_sort Jin, De
collection PubMed
description BACKGROUND: Diabetic distal symmetric polyneuropathy (DSPN) is one of the most common microvascular complications of diabetes mellitus, and it has become a major public health problem worldwide because of its high and increasing prevalence, morbidity, and disability rate. The current medications for DSPN are not entirely satisfactory. Preliminary studies indicated that the Chinese herbal TangBi Formula may alleviate signs and symptoms and improve the velocity of nerve conduction in patients with DSPN. This study was designed to determine if Chinese herbal medicine used in combination with conventional treatment is more effective than conventional treatment alone. METHODS/DESIGN: We are conducting a multicenter, placebo-controlled, double-blind, randomized, controlled clinical trial as a means of assessing the therapeutic effects of traditional Chinese medicine (TCM) treatment. A total of 188 patients will be randomized in a 1:1 ratio to a treatment group (TangBi Formula plus mecobalamin) and a control group (placebo plus mecobalamin). The test period lasts 6 months, during which all of the patients will be given standard medical care as recommended by established guidelines. The primary outcome will be development of differences in changes in clinical symptoms and signs in patients and changes in Michigan Diabetic Neuropathy Score (MDNS) between the two groups before and after treatment. The secondary outcome will be changes in nerve conduction velocity and in single clinical signs and symptoms. Safety assessments and adverse events will also be evaluated. DISCUSSION: We postulate that patients with DSPN will benefit from therapy that includes TCM. If successful, this work will provide an evidence-based complementary therapeutic approach for treatment of DSPN. TRIAL REGISTRATION: ClinicalTrials.gov, NCT03010241. Registered on 2 January 2017 ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13063-017-2345-1) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5747122
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-57471222018-01-03 Chinese herbal medicine TangBi Formula treatment of patients with type 2 diabetic distal symmetric polyneuropathy disease: study protocol for a randomized controlled trial Jin, De Huang, Wen-jing Meng, Xiang Yang, Fan Zheng, Yu-jiao Bao, Qi Zhang, Mei-zhen Yang, Ya-nan Ni, Qing Lian, Feng-mei Tong, Xiao-lin Trials Study Protocol BACKGROUND: Diabetic distal symmetric polyneuropathy (DSPN) is one of the most common microvascular complications of diabetes mellitus, and it has become a major public health problem worldwide because of its high and increasing prevalence, morbidity, and disability rate. The current medications for DSPN are not entirely satisfactory. Preliminary studies indicated that the Chinese herbal TangBi Formula may alleviate signs and symptoms and improve the velocity of nerve conduction in patients with DSPN. This study was designed to determine if Chinese herbal medicine used in combination with conventional treatment is more effective than conventional treatment alone. METHODS/DESIGN: We are conducting a multicenter, placebo-controlled, double-blind, randomized, controlled clinical trial as a means of assessing the therapeutic effects of traditional Chinese medicine (TCM) treatment. A total of 188 patients will be randomized in a 1:1 ratio to a treatment group (TangBi Formula plus mecobalamin) and a control group (placebo plus mecobalamin). The test period lasts 6 months, during which all of the patients will be given standard medical care as recommended by established guidelines. The primary outcome will be development of differences in changes in clinical symptoms and signs in patients and changes in Michigan Diabetic Neuropathy Score (MDNS) between the two groups before and after treatment. The secondary outcome will be changes in nerve conduction velocity and in single clinical signs and symptoms. Safety assessments and adverse events will also be evaluated. DISCUSSION: We postulate that patients with DSPN will benefit from therapy that includes TCM. If successful, this work will provide an evidence-based complementary therapeutic approach for treatment of DSPN. TRIAL REGISTRATION: ClinicalTrials.gov, NCT03010241. Registered on 2 January 2017 ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13063-017-2345-1) contains supplementary material, which is available to authorized users. BioMed Central 2017-12-29 /pmc/articles/PMC5747122/ /pubmed/29284520 http://dx.doi.org/10.1186/s13063-017-2345-1 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Study Protocol
Jin, De
Huang, Wen-jing
Meng, Xiang
Yang, Fan
Zheng, Yu-jiao
Bao, Qi
Zhang, Mei-zhen
Yang, Ya-nan
Ni, Qing
Lian, Feng-mei
Tong, Xiao-lin
Chinese herbal medicine TangBi Formula treatment of patients with type 2 diabetic distal symmetric polyneuropathy disease: study protocol for a randomized controlled trial
title Chinese herbal medicine TangBi Formula treatment of patients with type 2 diabetic distal symmetric polyneuropathy disease: study protocol for a randomized controlled trial
title_full Chinese herbal medicine TangBi Formula treatment of patients with type 2 diabetic distal symmetric polyneuropathy disease: study protocol for a randomized controlled trial
title_fullStr Chinese herbal medicine TangBi Formula treatment of patients with type 2 diabetic distal symmetric polyneuropathy disease: study protocol for a randomized controlled trial
title_full_unstemmed Chinese herbal medicine TangBi Formula treatment of patients with type 2 diabetic distal symmetric polyneuropathy disease: study protocol for a randomized controlled trial
title_short Chinese herbal medicine TangBi Formula treatment of patients with type 2 diabetic distal symmetric polyneuropathy disease: study protocol for a randomized controlled trial
title_sort chinese herbal medicine tangbi formula treatment of patients with type 2 diabetic distal symmetric polyneuropathy disease: study protocol for a randomized controlled trial
topic Study Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5747122/
https://www.ncbi.nlm.nih.gov/pubmed/29284520
http://dx.doi.org/10.1186/s13063-017-2345-1
work_keys_str_mv AT jinde chineseherbalmedicinetangbiformulatreatmentofpatientswithtype2diabeticdistalsymmetricpolyneuropathydiseasestudyprotocolforarandomizedcontrolledtrial
AT huangwenjing chineseherbalmedicinetangbiformulatreatmentofpatientswithtype2diabeticdistalsymmetricpolyneuropathydiseasestudyprotocolforarandomizedcontrolledtrial
AT mengxiang chineseherbalmedicinetangbiformulatreatmentofpatientswithtype2diabeticdistalsymmetricpolyneuropathydiseasestudyprotocolforarandomizedcontrolledtrial
AT yangfan chineseherbalmedicinetangbiformulatreatmentofpatientswithtype2diabeticdistalsymmetricpolyneuropathydiseasestudyprotocolforarandomizedcontrolledtrial
AT zhengyujiao chineseherbalmedicinetangbiformulatreatmentofpatientswithtype2diabeticdistalsymmetricpolyneuropathydiseasestudyprotocolforarandomizedcontrolledtrial
AT baoqi chineseherbalmedicinetangbiformulatreatmentofpatientswithtype2diabeticdistalsymmetricpolyneuropathydiseasestudyprotocolforarandomizedcontrolledtrial
AT zhangmeizhen chineseherbalmedicinetangbiformulatreatmentofpatientswithtype2diabeticdistalsymmetricpolyneuropathydiseasestudyprotocolforarandomizedcontrolledtrial
AT yangyanan chineseherbalmedicinetangbiformulatreatmentofpatientswithtype2diabeticdistalsymmetricpolyneuropathydiseasestudyprotocolforarandomizedcontrolledtrial
AT niqing chineseherbalmedicinetangbiformulatreatmentofpatientswithtype2diabeticdistalsymmetricpolyneuropathydiseasestudyprotocolforarandomizedcontrolledtrial
AT lianfengmei chineseherbalmedicinetangbiformulatreatmentofpatientswithtype2diabeticdistalsymmetricpolyneuropathydiseasestudyprotocolforarandomizedcontrolledtrial
AT tongxiaolin chineseherbalmedicinetangbiformulatreatmentofpatientswithtype2diabeticdistalsymmetricpolyneuropathydiseasestudyprotocolforarandomizedcontrolledtrial